Bausch Health Companies Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas J. Appio
- Full Time Employees
- 20,300
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2150 St. ElzEar Boulevard West Laval QC Canada H7L 4A8
- IPO Date
- Mar 29, 1994
- CIK
- 0000885590
- Website
- bauschhealth.com
- Similar Companies
- Business
- Bausch Health Companies Inc. develops, manufactures and markets a diversified portfolio of branded pharmaceuticals, generic pharmaceuticals, over-the-counter products and medical devices focused on gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics and ophthalmology; core offerings span Bausch + Lomb vision care products including contact lenses, intraocular lenses and ophthalmic surgical equipment, Salix gastrointestinal therapies such as Xifaxan, Ortho Dermatologics treatments like Retin-A Micro and Arazlo, Diversified neurology and pain medications including Wellbutrin and Relistor, Solta Medical aesthetic devices such as Thermage and Clear + Brilliant, and international branded generics and OTC products. Founded in 1959 and headquartered in Laval, Quebec, Canada, with U.S. operations in Bridgewater, New Jersey, the company conducts business directly or indirectly in over 90 countries across North America, Europe, the Middle East, Africa, Asia Pacific and Latin America through segments including Bausch + Lomb, Salix, International Rx, Ortho Dermatologics and Diversified Products. Recent developments include the completion of the DURECT Corporation acquisition in September 2025 adding larsucosterol, an FDA Breakthrough Therapy candidate for alcohol-associated hepatitis, to its hepatology pipeline; commercial expansion of the OraPharma division into Canada and Puerto Rico in November 2025 to enhance access to periodontal treatments like Arestin; acquisition of Chinese aesthetics distributor Wuhan Shibo Zhenmei Technology Co., Ltd. in December 2025; Canadian approvals and launches of CABTREO acne therapy in October 2024 and Thermage FLX in April 2025; and international regulatory nods for Clear + Brilliant Touch in multiple Asia Pacific markets in 2024-2025.
Company News
Best Value Stocks to Buy for September 22nd
Bausch Health Cos Inc. (NYSE:BHC) Receives $8.00 Consensus Target Price from Brokerages
Engineers Gate Manager LP Raises Stock Position in Bausch Health Cos Inc. $BHC
4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
Can Bausch (BHC) Run Higher on Rising Earnings Estimates?
Bausch (BHC) Upgraded to Buy: Here's What You Should Know
Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
Bausch Health: Q2 Beat And Cheap, But Debt Overhang Remains Substantial
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term
Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised
Bausch Health Companies Inc. (BHC) Q2 2026 Earnings Call Transcript
Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates
Bausch Health Cos Q2 Earnings Call Highlights